Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on discovering, developing, and commercializing innovative botanical drugs for inflammatory and immune diseases, leveraging a proprietary platform for phytomedicine research and development.

• Lead candidate, Phyto-N, is a botanical extract with preclinical evidence for multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout.

• Business model includes product sales, collaborations, licensing, and research grants, with initial revenue expected post-commercialization.

• Plans to submit an IND for ulcerative colitis in 1H 2026 and pursue a multi-indication strategy for Phyto-N.

Financial performance and metrics

• No revenue generated in 2023, 2024, or Q1 2025; net losses of $(361,506) in 2024 and $(137,583) in Q1 2025, reflecting R&D and IPO-related costs.

• Cash and cash equivalents were $198,943 as of March 31, 2025, supported by shareholder loans.

• Accumulated deficit of $(760,032) as of March 31, 2025; going concern disclosure included, but management believes recent financing and IPO proceeds will support operations for at least 12 months.

Use of proceeds and capital allocation

• Estimated net proceeds of $12.1M (or $14.2M if over-allotment exercised) at $4.00/share IPO price.

• Proceeds allocated to FDA-required GLP studies ($2M), clinical trial material manufacturing ($1M), Phase I trial ($3M), Phase II trial ($4M), and working capital/general purposes ($2.1M).

• Full business plan through FDA approval and launch estimated to require over $150M, with future phases dependent on additional financing.